Medisafe, a Boston, MA-based digital therapeutics company creating digital drug companions, raised $30m in Series C funding.
The round was led by Sanofi Ventures and Alive Israel HealthTech Fund, joined by Leumi Partners, Menorah Mivtachim and Consensus Business Group, previous investors Pitango HealthTech, 7wireVentures, Merck Ventures, Octopus Ventures, lool Ventures, Triventures, Qualcomm Ventures and Ourcrowd. In conjunction with the funding, Cris De Luca, Global Head, Digital Investments at Sanofi Ventures and David Klein, Co-Founder, Managing Partner ALIVE Israel HealthTech Fund will join Medisafe’s board of directors.
The company intends to use the funds to further expand its end-to-end solutions supporting patients managing medications and accelerate revenues growth.
Founded in 2012 and led by Omri Shor, CEO, Medisafe is a medication management platform with over 7M registered users globally. Partnering with global pharma companies and expanding opportunities across the health ecosystem, Medisafe deploys digital drug companions to holistically support patients throughout their unique therapy journey. Its advanced technology transforms patient behaviors powered by JITI™ (Just-in-Time-Interventions), AI data-driven personalized engine providing support for patients.
Over the past eight years, Medisafe has amassed a database of over four billion dosage behaviors informing JITI to maximize engagement and driving outcomes. In 2020, the company expanded its platform first launching Medisafe Care Connector which links the human element into patient support programs digitally connecting patients with clinicians. Last September, Medisafe introduced Maestro, a proprietary no-code technology to build, deploy and optimize personalized journeys.